{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:22:27Z","timestamp":1785363747530,"version":"3.55.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective cohort study including patients diagnosed neoplasm and 18 and older when receiving ICI therapy from 1\/1\/2011 to 12\/31\/2022. Queried ICD 9\/10 codes identified patients experiencing myocarditis, pericarditis, pericardial effusion, and cardiac tamponade within 1\u00a0year of ICI initiation. Survival analyses compared one-year overall survival (OS) of patients experiencing cardiac irAEs against propensity score matched populations not experiencing them.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 88,928 identified ICI patients, the incidence of myocarditis(0.48%), pericarditis(0.22%), and cardiac tamponade(0.47%) were less than 1% while pericardial effusion occurred in 4.71% of patients. Hazard ratios (HRs) were significantly higher in all cardiac irAE groups: myocarditis (HR:1.26, 95% CI:1.04\u20131.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), pericarditis (HR:1.36, 95% CI:1.02\u20131.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), pericardial effusion (HR:1.49, 95% CI:1.39\u20131.59, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), cardiac tamponade (HR:2.15, 95% CI:1.79\u20132.57, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and overall pericardial disease (HR:1.46, 95% CI:1.37\u20131.56, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). There was no significant difference in OS between myocarditis and pericarditis or overall pericardial diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion\/conclusion<\/jats:title>\n            <jats:p>Utilizing a uniquely large cohort of ICI patients, this study further shows the rarity of cardiac inflammatory irAEs and highlights their significant impact on patient survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40959-025-00300-1","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:25:56Z","timestamp":1741148756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Aya F.","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Doh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nareh","family":"Nowrouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"300_CR1","doi-asserted-by":"publisher","unstructured":"Gong J, Drobni ZD, Zafar A, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(6) https:\/\/doi.org\/10.1136\/jitc-2021-002771","DOI":"10.1136\/jitc-2021-002771"},{"issue":"16","key":"300_CR2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"300_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, et al. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOncol. 2022;4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"300_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31662\/jmaj.2021-0001","volume":"4","author":"H Kadowaki","year":"2021","unstructured":"Kadowaki H, Akazawa H, Ishida J, Komuro I. Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events. JMA J. 2021;4(2):91\u20138. https:\/\/doi.org\/10.31662\/jmaj.2021-0001.","journal-title":"JMA J"},{"issue":"5","key":"300_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaccao.2022.06.008","volume":"4","author":"F Thuny","year":"2022","unstructured":"Thuny F, Bonaca MP, Cautela J. What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis? JACC CardioOncol. 2022;4(5):624\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2022.06.008.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"300_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40959-024-00234-0","volume":"10","author":"SE Mudra","year":"2024","unstructured":"Mudra SE, Rayes DL, Agrawal A, et al. Immune checkpoint inhibitors and pericardial disease: a systematic review. Cardiooncology. 2024;10(1):29. https:\/\/doi.org\/10.1186\/s40959-024-00234-0.","journal-title":"Cardiooncology"},{"key":"300_CR7","doi-asserted-by":"crossref","unstructured":"Fox B, Backes F. Varying presentations of immune checkpoint inhibitor-associated myocarditis: A case report of the clinical characteristics and outcomes of three patients. Gynecol Oncol Rep. \u00a9 2023 Published by Elsevier Inc.; 2023:101271.","DOI":"10.1016\/j.gore.2023.101271"},{"key":"300_CR8","unstructured":"Manda YR, Baradhi KM. Myopericarditis. StatPearls. StatPearls Publishing. Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023."}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:25:58Z","timestamp":1741148758000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00300-1","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using de-identified data, and thus did not require Institutional Review Board (IRB) or ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}